When Is a GLP-1 Too Potent? Retatrutide’s 28% Weight Loss | Denver

Retatrutide’s 28% Weight Loss Is Eye-Opening. But Is More Always Better?

Eli Lilly dropped a bombshell earlier this month: their next-generation obesity drug retatrutide helped patients lose up to 28% of their body weight over 80 weeks in a Phase 3 trial. That’s not a rounding error on existing data — that’s a meaningful jump over what Zepbound and Wegovy deliver, and it’s putting the entire GLP-1 field on notice.

Here’s what we know from the TRIUMPH-1 trial, released May 21: participants who stayed on retatrutide for about a year and a half averaged a 28% reduction in body weight. A lower dose came in around 19% — still competitive with today’s best options, and with fewer people quitting due to side effects.

For context:

• Zepbound (tirzepatide): ~20–21% average weight loss
• Wegovy (semaglutide): ~14–15% average weight loss
• Retatrutide (triple agonist): ~28% average weight loss

That’s a meaningful step up. But as the Washington Post reported this week, doctors are starting to ask a harder question: at what point does the efficacy trade-off not be worth it?

Why Potency Isn’t Everything

More weight loss sounds like a clear win. But higher-potency drugs often carry a heavier side-effect burden — more nausea, more GI disruption, more patients discontinuing. The 19% dose in the trial showed better tolerability than the higher dose, which raises an obvious question: should we be chasing 28% when 19% comes with less misery?

There are also genuine unknowns about long-term safety at these higher efficacy levels. We’re not dealing with marginal improvements — we’re talking about drugs that are fundamentally reshaping metabolic biology. The regulatory review for retatrutide is ongoing, and those questions won’t be resolved until we have more real-world data.

What this means for you:

• Next-generation GLP-1s are coming — retatrutide is likely next in line for FDA approval
• Higher efficacy options are valuable, but tolerability matters. A drug you can stay on beats a “better” drug you quit
• The field is moving toward shared decision-making: what level of weight loss justifies what level of side effects for you?

Denver has been at the forefront of GLP-1 adoption for years, and CNC patients are already asking about these newer options. I’ll be watching the FDA review closely. When retatrutide gets approved — likely in 2027 — we’ll have another tool in the cabinet.

Stay tuned.